Take off with Nektar Therapeutics (NKTR): Get ready for trading

With 3.6 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.6 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.0200 whereas the lowest price it dropped to was $0.8999. The 52-week range on NKTR shows that it touched its highest point at $1.12 and its lowest point at $0.41 during that stretch. It currently has a 1-year price target of $3.00. Beta for the stock currently stands at 0.91.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NKTR was up-trending over the past week, with a rise of 6.97%, but this was up by 21.79% over a month. Three-month performance surged to 68.14% while six-month performance rose 59.50%. The stock gained 49.37% in the past year, while it has gained 68.14% so far this year. A look at the trailing 12-month EPS for NKTR yields -1.46 with Next year EPS estimates of -0.71. For the next quarter, that number is -0.19. This implies an EPS growth rate of 38.97% for this year and 19.49% for next year.

Float and Shares Shorts:

At present, 191.38 million NKTR shares are outstanding with a float of 178.15 million shares on hand for trading. On Mar 15, 2024, short shares totaled 2.51 million, which was 1.37% higher than short shares on Feb 15, 2024. In addition to NTR as the firm’s Nutrien Ltd., NKTR serves as its Nektar Therapeutics.

Institutional Ownership:

Through their ownership of 67.25% of NKTR’s outstanding shares, institutional investors have majority control over the company.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for NKTR since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.

Dividends & Yield:

In terms of dividends, NKTR has a current ratio of $––, which is $–– over the trailing 12-months, while a dividend of $–– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and NKTR currently yields $0.00. In the past year, NKTR’s dividend yield has been $0.00, but when looking at the stock over the past five years, its yield has been $–. Accordingly, NKTR has a current buyback yield of $–. This was $– for the TTM, and it was $– for the past five years.